Evidence map›Paper›PMID 42588432›Full record

ArticleMolecules (Basel, Switzerland)2026

Chondroitin Sulfate-Based Self-Assembling Nanoprodrug for Controlled Methotrexate Delivery in Cancer Therapy.

Ludovica Scorzafave, Michele Pellegrino, Giuseppe Cirillo, Marco Fiore, Roberta Pino, Diana Amantea, Antonella Leggio, Fiore Pasquale Nicoletta, Francesca Iemma, Manuela Curcio

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ludovica ScorzafaveDepartment of Pharmacy Health and Nutritional Science, University of Calabria, 87036 Rende, Italy.
Michele PellegrinoDepartment of Pharmacy Health and Nutritional Science, University of Calabria, 87036 Rende, Italy.
Giuseppe CirilloDepartment of Pharmacy Health and Nutritional Science, University of Calabria, 87036 Rende, Italy.ORCID 0000-0002-9592-1333
Marco FioreDepartment of Pharmacy Health and Nutritional Science, University of Calabria, 87036 Rende, Italy.
Roberta PinoDepartment of Pharmacy Health and Nutritional Science, University of Calabria, 87036 Rende, Italy.ORCID 0009-0005-7252-7340
Diana AmanteaDepartment of Pharmacy Health and Nutritional Science, University of Calabria, 87036 Rende, Italy.ORCID 0000-0002-7513-3495
Antonella LeggioDepartment of Pharmacy Health and Nutritional Science, University of Calabria, 87036 Rende, Italy.ORCID 0000-0002-4373-6232
Fiore Pasquale NicolettaDepartment of Pharmacy Health and Nutritional Science, University of Calabria, 87036 Rende, Italy.ORCID 0000-0001-5961-1963
Francesca IemmaDepartment of Pharmacy Health and Nutritional Science, University of Calabria, 87036 Rende, Italy.ORCID 0000-0001-9548-0446
Manuela CurcioDepartment of Pharmacy Health and Nutritional Science, University of Calabria, 87036 Rende, Italy.ORCID 0000-0003-2026-0152

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, a pH-responsive chondroitin sulfate-methotrexate (MTX) polymeric prodrug was synthesized through Schiff base formation between oxidized chondroitin sulfate and MTX. The resulting amphiphilic conjugate exhibited a conjugation degree of 184 mg MTX per g conjugate and spontaneously self-assembled into stable nanoparticles (CSMXPs) with a mean diameter of 120 ± 10 nm, a polydispersity index of 0.24, and a critical aggregation concentration of 4.7 × 10

Indexed as

Antineoplastic AgentsChondroitin SulfatesDrug Delivery SystemsMethotrexateNanoparticlesNeoplasmsProdrugsCell Line, TumorCell SurvivalDrug CarriersDrug LiberationHeLa CellsHumansHydrogen-Ion ConcentrationAntineoplastic AgentsChondroitin SulfatesDrug CarriersMethotrexateProdrugscancer therapychondroitin sulfatemethotrexatepH-responsive polymeric prodrugself-assembling nanoparticles

Identifiers

PMID42588432
PMCPMC13468386

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.